Saturday, 31 October 2026European Markets

PGS Stock Was Up By 12.15% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with PGS (PGS.OL) jumping 12.15% to kr8.82 on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI jumped 0.13% to kr1,352.65, following the last session's downward trend on what was a somewhat up trend trading session today.

PGS's last close was kr7.86, 24.71% under its 52-week high of kr10.44.

About PGS

PGS ASA, together with its subsidiaries, operates as a marine geophysical company primarily in Norway. The company provides a range of seismic and reservoir services, including data acquisition, imaging, interpretation, and field evaluation to oil and gas companies, as well as carbon storage and offshore wind markets. It also operates in the Asia Pacific, Canada, Egypt, the Americas, Angola, the United Kingdom, Greece, Cyprus, Ukraine, Brazil, South Africa, other African countries, the Middle East, and internationally. The company was formerly known as Petroleum Geo-Services ASA and changed its name to PGS ASA in May 2019. PGS ASA was founded in 1991 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PGS has a trailing twelve months EPS of kr-0.97.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.79%.

Sales Growth

PGS's sales growth is 8.4% for the ongoing quarter and 47.3% for the next.

Volume

Today's last reported volume for PGS is 19353700 which is 309.38% above its average volume of 4727490.

Revenue Growth

Year-on-year quarterly revenue growth grew by 22.3%, now sitting on 721.5M for the twelve trailing months.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 100% and 1000%, respectively.

More news about PGS (PGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com